Date: 18 March 2023 Your Name: Ashiq Abdul Khader Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	lectures, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Leadersh in other committe group, participal services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory 10 Leadershin other committigroup, progroup, program, p	Monitoring Board or		
 10 Leadersh in other committing roup, particular sector sec			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 18 March 2023 Your Name: Aina Pons Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	lectures, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Leadersh in other committe group, participal services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory10Leadersh in other committi group, pr11Stock or12Receipt of materials writing, g services	Monitoring Board or		
 10 Leadersh in other committing roup, particular sector sec			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 18 March 2023 Your Name: Abigail Palmares Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	lectures, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committi group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Leadersh in other committe group, participal services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory10Leadersh in other committi group, pr11Stock or12Receipt of materials services	Monitoring Board or		
 10 Leadersh in other committe group, particular sector of the sector of t			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 18 March 2023 Your Name: Sarah Ann Booth Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	lectures, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Stock or Receipt of materials writing, generation services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory 10 Leadershin other committigroup, progroup, program, p	Monitoring Board or		
 10 Leadersh in other committing roup, particular sector sec			
 in other committing group, particular 11 Stock or 12 Receiption materials writing, services 	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 14 April 2023 Your Name: Alexander Smith Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Society of Cardiothoracic Surgery & AstraZeneca	Recipient of the 2021 Society for Cardiothoracic Surgery and AstraZeneca Thoracic Oncology Fellowship
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

Recipient of the [2021] Society for Cardiothoracic Surgery and AstraZeneca Thoracic Oncology Fellowship

Please place an "X" next to the following statement to indicate your agreement:

Date: 18 March 2023 Your Name: Chiara Proli Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

lectures, speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Iectures, speakers manuscr education6Payment testimon7Support meetings7Support meetings8Patents p pending9Participal Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of material writing, g services			
Speakers manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	nt or honoraria for	XNone	
manuscr educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Patents p safety M Advisory10Leadersh in other committ group, pi11Stock or materials writing, g services	lectures, presentations,		
educatio6Payment testimon7Support meetings7Support meetings8Patents p pending9Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, patents11Stock or materials writing, g services	-		
 Payment testimon Support meetings Patents pending Participa Safety M Advisory Leadersh in other committe group, patents pending Stock or Receipt of materials writing, generation services 	cript writing or		
testimon7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Number7Support meetings7Support meetings8Patents p pending9Participa Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	nt for expert	XNone	
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 	ony		
 Patents pending Participa Safety M Advisory Leadersh in other committe group, patents Stock or Receipt of materials writing, generations 			
 Patents pending Participa Safety M Advisory Leadersh in other committe group, participal safety M Advisory Leadersh in other committe group, participal services 	rt for attending	XNone	
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g	ngs and/or travel		
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g			
9 Participa Safety M Advisory 10 Leadersh in other committ group, pi 11 Stock or 12 Receipt of materials writing, g services	s planned, issued or	XNone	
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services			
Safety M Advisory10Leadersh in other committ group, pi11Stock or12Receipt of materials writing, g services	pation on a Data	X None	
Advisory10Leadersh in other committi group, pr11Stock or12Receipt of materials writing, g services	Monitoring Board or		
 10 Leadersh in other committe group, particular sector of the sector of t			
 in other committing roup, particular providence of the second seco	ship or fiduciary role	X None	
committe group, pi11Stock or12Receipt of materials writing, g services	er board, society,		
group, pa 11 Stock or 12 Receipt of materials writing, g services	ittee or advocacy		
11Stock or12Receipt of materials writing, g services	paid or unpaid		
12 Receipt of materials writing, g services		X None	
materials writing, g services			
materials writing, g services			
materials writing, g services			
writing, g services	t of equipment,	X_None	
services	als, drugs, medical		
	_		
13 Other fin			
	financial or non-	XNone	
financial	al interests		
		XNone	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: 18 March 2023 Your Name: Paulo De Sousa Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Vitae Professionals	Speaking & Lecture Fees
		Boehringer Ingelheim Ltd	Speaking & Lecture Fees
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Takeda Oncology	Conference fees and travel
		Lilly	Conference fees and travel
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Paulo De Sousa reports a relationship with: Takeda Oncology and Lilly that includes: conference fees and travel fees, Vitae Professionals and Boehringer Ingelheim Ltd that includes: speaking and lecture fees

Please place an "X" next to the following statement to indicate your agreement:

Date: 27 May 2023 Your Name: Eric Lim Manuscript Title: Outcomes of chest drain management using only air leak (without fluid) criteria for removal after general thoracic surgery – a drainology study Manuscript number (if known): JTD-22-1810

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.				
		Time frame: past	36 months		
2	Grants or contracts from	AstraZeneca	Funding Grants		
	any entity (if not indicated	Pharmaceuticals LP			
	in item #1 above).	Boehringer Ingelheim Ltd	Funding Grants		
		Medela Inc	Funding Grants		
		Lilly	Funding Grants		
3	Royalties or licenses	None			

4	Consulting fees	Johnson & Johnson	Consulting/Advisory
		Services Inc	Consulting (Advisory
		Ethicon Inc Covidien	Consulting/Advisory Consulting/Advisory
		Medtronic Inc Guardant Health Inc	Consulting/Advisory Consulting/Advisory
		BeiGene	Consulting/Advisory
		Roche	
		BMS Institute of	Consulting/Advisory
		Technology Management	Consulting/Advisory
		AstraZeneca	Consulting/Advisory
		Pharmaceuticals LP	
		Boehringer Ingelheim Ltd	Consulting/Advisory
		Medela Inc	Consulting/Advisory
		Lilly	Consulting/Advisory
5	Payment or honoraria for	None	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
	-		
8	Patents planned, issued or	#P52435GB	Issued to Licensee
	pending	#P57988GB	Issued to Licensee
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	My Cancer Companion	Founder
	in other board, society,	Healthcare	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	VIOLET NIHR HTA (13/03/03)	Chief Investigator
		MARS 2 NIHR HTA (15/188/31)	Chief Investigator
		RAMON NIHR HTA	Chief Investigator
		(131306)	

Eric Lim reports a relationship with:

Johnson & Johnson Services Inc that includes: consulting or advisory, Ethicon Inc that includes: consulting or advisory, Covidien that includes: consulting or advisor, Medtronic Inc that includes: consulting or advisory, Guardant Health Inc that includes: consulting or advisory, BeiGene that includes: consulting or advisory, Roche that includes: consulting or advisory, BMS Institute of Technology and Management that includes: consulting or advisory, AstraZeneca Pharmaceuticals LP that includes: consulting or advisory and funding grants, Boehringer Ingelheim Ltd that includes: consulting or advisory and funding grants, Medela Inc that includes: consulting or advisory and funding grants.

Has patent #P52435GB and patent #P57988GB issued to Licensee. Chief Investigator of the following trials: VIOLET NIHR HTA (13/04/03), MARS 2 NIHR HTA (15/188/31), RAMON NIHR HTA (131306).

Dr. Lim is the founder of My Cancer Companion Healthcare.

Please place an "X" next to the following statement to indicate your agreement: